Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for oncology, addressing critical unmet needs in cancer treatment. Stemline Therapeutics, Inc. was founded in 2003 and is headquartered in New York, US.

The company specializes in the field of oncology and has undergone several funding rounds, culminating in an IPO in January 2013, where it raised USD 33 mn. The CEO is Ivan Bergstein, and the firm has completed a total of 4 deals. Stemline Therapeutics develops proprietary oncology products, including ELZONRIS (tagraxofusp-erzs) for treating blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative advanced breast cancer. These products are primarily marketed in North America and Europe, targeting healthcare professionals and specialized oncology centers.

In the most recent year reported, 2019, Stemline Therapeutics generated revenue of USD 43. 22 mn, with an EBITDA of USD -79. 15 mn. Revenue is primarily derived from the sales of its oncology drugs through direct transactions with healthcare providers, hospitals, and pharmacies, informed by market conditions and treatment guidelines.

Following its IPO in January 2013, Stemline Therapeutics aims to leverage the funds raised to enhance its product pipeline and expand market reach. The company plans to launch new oncology therapies and target international markets in Europe and Asia by 2025. Recent strategic initiatives will further support these efforts, focusing on maximizing distribution and accessibility of its innovative treatments.